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Background/objective: Hematopoietic stem cell transplant (HSCT) is the only curative treat-
ment for myeloproliferative neoplasm-associated myelofibrosis (MPN-MF). The main clinical
manifestation of MPN-MF is splenomegaly secondary to extramedullary hematopoiesis (EMH).
The effects of HSCT on splenic EMH and associated vascular and stromal changes are unknown.
This study compares the findings seen in spleens following HSCT with those of nontransplanted
patients, normal controls, and matched bone marrow (BM) samples.
Methods: This study included three transplanted MPN-MF spleens, three nontransplanted MPN-
MF spleens, and three normal controls. Spleens were assessed for: (a) presence/extent of EMH;
(b) presence of Gamna–Gandy bodies; (c) splenic fibrosis; (d) CD34-positive microvessel den-
sity; (e) CD8-positive sinusoids; (f) frequency of smooth muscle actin-positive myoid cells;
and (g) nerve growth factor receptor-positive adventitial reticulum cells. In two cases,plant; MF,
nditioning
m ST-707,
Post-transplant spleen histology in myelofibrosis 97matched BM samples were assessed for cellularity, presence of atypical megakaryocytes, and
fibrosis.
Results: Compared with normal controls, all MPN-MF spleens were larger in size, had EMH, red
pulp fibrosis, higher CD34-positive microvessel density, and decreased CD8-positive sinusoids.
Compared with nontransplanted cases, post-HSCT spleens showed disappearance or reduction
of EMH. Gamna–Gandy bodies were increased; no differences in the remaining parameters
were found. A reduction of splenic EMH was associated with normalization of BM cellularity
and megakaryopoiesis.
Conclusion: HSCT reduces/abrogates splenic EMH and is associated with an increased number
of Gamna–Gandy bodies, which may suggest vascular damage. The lack of stromal changes in
spleens removed shortly after transplant is in line with similar observations in the BM, where a
longer interval is often necessary for resolution of fibrosis.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Primary myelofibrosis (PMF), polycythemia vera (PV), and
essential thrombocythemia (ET) are Philadelphia-negative
myeloproliferative neoplasms (MPN), which originate from
the neoplastic transformation of marrow hematopoietic
stem cells [1–3]. Although PMF, PV, and ET are distinct
oncological entities, their advanced myelofibrotic stages
share several clinicopathological features [4,5] and are col-
lectively referred to as MPN-associated myelofibrosis (MF).
One of the distinct clinical features of MPN-MF is the
presence of splenomegaly [6], which is the direct conse-
quence of extramedullary hematopoiesis (EMH), by which
proliferating hematopoietic cells expand and efface the
splenic architecture [7,8]. Several theories have originally
addressed the pathobiology of EMH in MPN-MF: (a) the com-
pensatory theory, considering EMH as a compensatory reac-
tion to extensive bone marrow (BM) fibrosis; (b) the
myelostimulatory theory, hypothesizing the reactivation of
dormant splenic hematopoiesis in response to MF-derived
cytokines; and (c) the neoplastic theory, considering EMH
as the splenic localization of neoplastic hematopoietic cells
[9]. From the 1980s onward, the neoplastic nature of splenic
EMH was definitely proven by its association with cytoge-
netic abnormalities, presence of clonal X chromosome inac-
tivation, and of JAK2V617F mutation [10–15].
It is currently believed that EMH in MPN spleens is asso-
ciated with abnormal trafficking of BM-derived clonal
hematopoietic progenitors and stem cells, due to the dys-
regulation of the marrow microenvironment. This results
in circulating mature and immature marrow elements that
home to the spleen. These cells are largely capable of pro-
ducing the typical histologic manifestation of EMH, that is,
trilinear hematopoiesis including erythroblasts, myeloid
precursors with a predominance of maturing forms, and
megakaryocytes.
Splenic EMH is largely centered on the splenic red pulp,
induces marked atrophy of the white pulp, with disappear-
ance of B-cells and reduction of T-cell perivascular cuffs
[16–18]. EMH proliferates with a diffuse, nodular, or mixed
growth pattern [16,17]. In addition, MPN-MF is capable of
affecting both red pulp vessels and stromal cells, with a
marked decrease of CD8-positive splenic sinusoids and aparallel increase of CD34-positive microvessels and intersti-
tial fibrosis. These changes were confirmed by the demon-
stration of an altered distribution of smooth muscle actin
(SMA)-positive myoid cells and of nerve growth factor
receptor (NGFR)-positive adventitial reticulum cells [16].
Of note, none of these studies included spleens obtained
following hematopoietic stem cell transplant (HSCT).
The present study thus aims to describe the histologic
changes induced by HSCT in spleens of MPN-MF patients.
The morphological and immunohistochemical features of
such cases were compared with those of spleens from non-
transplanted MF patients and with normal controls. Possible
correlations between post-HSCT spleen and BM findings
(i.e., cellularity, presence of atypical megakaryocytes,
and presence of fibrosis) were also studied.
Materials and methods
Case selection
The present study considered a single Institution series of
patients with history of MPN-MF, treated with HSCT. Among
18 patients with an enlarged spleen at the time of HSCT, 14
had documentation of the spleen status after HSCT. Four
patients had normalization of the spleen size, seven
patients had persistent splenomegaly, and three patients
underwent splenectomy due to poor count recovery.
The present study focused on the histologic and immuno-
histochemical features of the spleens removed from the lat-
ter three patients (2 men and 1 woman; age: 55 years,
52 years, and 33 years). Two cases had a diagnosis of PMF
and one case had post-PV MF. Pretransplant clinical data
(i.e., Lille score, Dynamic International Prognostic Scoring
System score, Eastern Cooperative Oncology Group perfor-
mance status, number of circulating blasts, lactic acid dehy-
drogenase levels) and post-transplant follow-up were
available in all cases. The response to therapy was assessed
according to the revised International Working Group-
Myeloproliferative Neoplasms Research and Treatment and
European LeukemiaNet criteria [19]. BM biopsies after
splenectomy were available in two cases.
Data on JAK2 mutational status were available for both
transplanted and nontransplanted MF: three out of six
98 M. Pizzi et al.patients carried the JAK2V617F mutation (post-HSCT MF: 1
case; nontransplanted MF: 2 cases); three out of six cases
were JAK2V617F-negative (post-HSCT MF: 2 cases; nontrans-
planted MF: 1 case). No information on MPL and/or CALR
mutations was available for the JAK2V617F-negative cases.
The morphological and immunohistochemical features of
post-HSCT spleens were compared with: (a) three spleens
obtained from nontransplanted MF patients (2 men and 1
women; age: 72 years, 71 years, and 63 years), with compa-
rable marrow fibrosis and disease stage (PMF: 2 cases; post-
PV MF: 1 case); (2) three normal spleens, removed during
major abdominal surgery for nonhematological malignan-
cies (3 men; age: 76 years, 69 years, and 54 years). In both
the transplanted and nontransplanted MF subgroups,
splenectomy was performed at comparable time intervals
after the diagnosis of MPN. In particular, the transplanted
patients were splenectomized 4 years, 2 years, and 15 years
after the original diagnosis of MPN (mean time interval
between diagnosis and splenectomy: 7.0 years). The non-
transplanted patients underwent splenectomy 2 years,
4 years, and 23 years after the original diagnosis of PMF or
PV (mean time interval: 9.7 years).
Paraffin embedded tissue blocks were retrieved from the
archives of the Hematopathology Division of Weill Cornell
Medical College, New York, NY. Gross descriptions of each
case (weight and size of the spleen and presence of infarcts
and/or other focal lesions) were available in all cases.
For each case, appropriate informed consent was
obtained. The study was also approved by the Institutional
Review Board, consistent with the Declaration of Helsinki.
Histologic evaluation of the spleen
Representative formalin-fixed, paraffin-embedded tissue
blocks were selected for histologic evaluation. The follow-
ing morphological parameters were evaluated: (a) presence
and extent of EMH, graded using a 4-tiered score (score
0 = absent; score 1+ = rare clusters of 65 cells; score 2+:
either several clusters of 5–10 cells or any clusters of 50
cells; and score 3+ = numerous small clusters or areas of dif-
fuse involvement) [17]; (b) EMH growth pattern (nodular,
diffuse, or mixed, as previously reported) [16]; (c) EMH cel-
lular composition; (d) presence of splenic infarcts; (e) pres-
ence of Gamna–Gandy bodies (i.e., sclero-siderotic
nodules); and (f) presence of splenic fibrosis (as assessed
by reticulin and trichrome stains). Splenic fibrosis was
defined as the presence of reticulin/collagen fibers exceed-
ing what was observed in normal controls (i.e., fine fibers
around the splenic vessels and red pulp sinusoids).
For the comparison between post-HSCT spleens and BMs,
the following marrow parameters were considered: (a) BM
cellularity; (b) presence of atypical megakaryocytes (i.e.,
megakaryocytes with large, bulbous nuclei); (c) presence
and extent of BM fibrosis (as assessed according to the
2008 World Health Organization MF-scoring system) [1].
Immunohistochemical analysis
The architecture and immunohistochemical features of
splenic stroma and red pulp vessels were assessed using
antibodies against the following antigens: CD34 (cloneQBEND/10; Leica Microsystems, Buffalo Grove, IL, USA),
CD8 (clone C8/144B; Dako, Carpinteria, CA, USA), NGFR
(clone ME20.4; Abcam, Cambridge, MA, USA), and SMA
(clone 1A4; Dako). Antigen detection was performed with
the Leica Refine Polymer Detection kit, using an automated
BOND III immunostainer (Leica Biosystems). In MPN-MF
cases, the number of SMA-positive and NGFR-positive stro-
mal cells was assessed by comparison with control spleens
and graded as increased, normal, or reduced. The density
of CD8-positive splenic sinusoids and CD34-positive
microvessels was esteemed by manually counting at least
10 representative high-power fields (HPF). For comparison
between normal spleens, transplanted and nontransplanted
MPN-MF cases, the mean values of CD34 and CD8 density
were considered.
Results
Clinical–epidemiological features of the study
population
To evaluate the splenic histologic response to HSCT in MPN-
MF, the present study considered three subgroups of
patients: (a) patients with a history of MPN-MF, treated with
HSCT; (b) patients with history of MPN-MF, treated with
conventional therapies other than HSCT; and (c) patients
without hematological malignancies, who underwent
splenectomy during major abdominal surgery. The clinico-
pathological features of each subgroup are reported in
Table 1.
The post-HSCT MF subgroup included two men and one
woman (mean age at splenectomy, 46.7 years; range, 33–
55 years). Pretransplant Lille score, Dynamic International
Prognostic Scoring System score, Eastern Cooperative
Oncology Group performance status, number of circulating
blasts, and lactic acid dehydrogenase levels are reported
in Table 2. In all cases, HSCT was performed using periph-
eral mobilized blood stem cells from matched unrelated
donors and reduced-intensity conditioning regimens (flu-
darabine plusmelphalan: 2 cases; fludarabine plus busulfan:
1 case; Table 2) [20,21]. Complete histologic response in the
BM was achieved in all cases at different time points after
HSCT: two cases (#1 and #2) achieved complete histologic
response <3 months after transplant; one case (#3) attained
only partial response 1 year after HSCT, but subsequent
follow-up showed complete clinical and histologic response
(CR) [19]. Of note, the patient attained CR after splenec-
tomy without any further treatment. As for the long-term
outcome, two patients (Cases #1 and #2) died of infectious
complications 3.7 months and 14.8 months after HSCT,
before complete normalization of the peripheral blood
counts; one patient (Case #3) is alive and in CR 29.5 months
after HSCT.
Post-HSCT splenectomy was performed due to refractory
thrombocythopenia (Cases #1 and #2) or refractory cytopenia
with hemolysis (Case #3). At the time of splenectomy, the lat-
ter patient presented with atypical hemolytic uremic syn-
drome. The mean interval between HSCT and splenectomy
was 102.7 days (56 days in Case #1; 76 days in Case #2; and
176 days in Case #3). At the time of splenectomy, all patients
were under treatment with tacrolimus (Tables 1 and 2).
Table 1 Clinico-pathological features of the study population.
Patient Group Sex Age (y) Diagnosis Post-HSCT
(d)
Spleen
weight (g)
Ganma–Gandy
bodies
EMH
score
EMH pattern EMH
lineage
Fibrosis CD34+
vessel
densityb
CD8+
sinusoid
densityb
SMA+ & NGFR+
cells
1 Post-HSTC MFa M 55 PMF 56 3100 Present 0 –c –c Present 42.1 19.5 Increased
2 Post-HSTC MFa F 52 Post-PV PMFd 76 1540 Present 1+ Diffuse Erythroid Present 35.8 11 Increased
3 Post-HSTC MFa M 33 PMF 176 2560 Present 2+ Nodular and diffuse Mixed Present 38.5 15.3 Increased
4 Nontransplanted MF M 71 PMFd NA 5400 Absent 3+ Nodular and diffuse Mixed Present 41.4 29.5 Increased
5 Nontransplanted MF M 63 PMF NA 1126 Rare 3+ Nodular and diffuse Mixed Present 39.9 10.2 Increased
6 Nontransplanted MF F 72 Post-PV PMFd NA 2933 Absent 3+ Nodular and diffuse Mixed Present 39.2 17.8 Increased
7 Normal control M 76 LMS NA 120 Absent 0 –c –c Absent 27.1 48.6 Normal pattern
8 Normal control M 54 Esophageal
carcinoma
NA 58 Absent 0 –c –c Absent 34.2 46.1 Normal pattern
9 Normal control M 69 Pancreatic
carcinoma
NA 150 Absent 0 –c –c Absent 32.7 41.2 Normal pattern
Note. EMH = extramedullary hematopoiesis; F = female; HSCT = hemopoietic stem cell transplant; LMS = leiomyosarcoma; M = male; NA = not applicable; PMF = primary myelofibrosis;
PV = polycythemia vera.
a GVHD prophylaxis/other treatments at the time of splenectomy: tacrolimus (patients 1 and 2); tacrolimus plus methylprednisone (patient 3).
b Number of vessels/10 high power fields.
c No EMH identified.
d JAK2V617F-positive case.
Table 2 Detailed clinical features and outcome of the three transplanted patients.
Patient # Lille
Scorea
DIPPS
Scorea
ECOG
Scorea
Peripheral
blasts
(per 103 WBC)a
LDH (IU/L)a Conditioning CD34 dose
(106/kg)
Indication to splenectomy Response to splenectomy Outcome Survival (mo)
1 Int Int-2 1 16 1260 Flu/mel 10.5 Refractory thrombocytopenia Normalization of platelet count Dead of infection 14.8
2 High High 2 8 288 Flu/mel 6.4 Refractory thrombocytopenia Too short time to assess response. Dead of infection 3.7
3 Int Int-2 2 11 668 Flu/bu 4.7 Pancytopenia and hemolysis Normalization of blood counts Alive 29.5
Note. DIPSS = Dynamic International Prognostic Scoring System; ECOG = Eastern Cooperative Oncology Group; Flu/bu = fludarabine plus busulfan; Flu/mel = fludarabin plus melphalan;
LDH = lactic acid dehydrogenase.
a Values before hemopoietic stem cell transplant.
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Fig. 1 Representative histologic features of the studied spleens. A-D. Post-HSCT MPN-MF spleens. The spleens from transplanted
MF patients disclosed a marked reduction of EMH with abundant Gamna-Gandy bodies (A). Residual hemopoietic aggregates were
small and mainly composed of erythroid precursors (B). Reticulin (C) and trichrome (D) stain disclosed marked splenic fibrosis with
deposition of collagen fibers. E-H. Nontransplanted MPN-MF spleens. The spleens from nontransplanted patients were characterized
by striking EMH (E), with large clusters of atypical megakaryocytes (F). However, with reticulin (G) and trichrome (H) stains, the
degree of splenic fibrosis was similar to that oserved in transplanted MF. I-L. Normal controls. Normal spleens showed a normally
preserved white pulp (I), with no evidence of EMH (J). Reticulin (K) and trichrome (L) stain showed absence of fibrosis. (H&E,
reticulin and trichrome stains; original magnification 10x and 20x).
100 M. Pizzi et al.The nontransplanted MPN-MF subgroup included two men
and one woman (mean age at splenectomy, 68.7 years;
range, 63–72 years). These patients were treated with
cytoreductive therapies, including cladribine plus ruxoli-
tinib, interferon-a plus hydroxyurea, and hydroxyurea alone
(1 case each). Splenectomy was performed for severe and
untreatable cytopenia (2 cases) or massive splenomegaly
(1 case). HSCT was not performed due to poor performance
status, excessive comorbidities, and/or unavailability of a
suitable graft. The normal spleen subgroup encompassed
three men, with a mean age at splenectomy of 66.3 years
(range, 54–76 years). These patients underwent splenec-
tomy during major abdominal surgery for malignant tumors
(leiomyosarcoma, esophageal carcinoma, and pancreatic
carcinoma: 1 case each). Gross and histologic examination
of the spleen excluded the presence of metastatic disease.
Spleen pathology in transplanted and
nontransplanted MPN-MF
The spleens in transplanted and nontransplanted MPN-MF
were markedly enlarged compared with normal controls
(Table 1). The mean weight of post-HSCT spleens was lower
than nontransplanted cases (mean spleen weight: 2400 g in
post-HSCT MPN-MF; 3153 g in nontransplanted MPN-MF).
Subcapsular infarcts were present in both transplantedand nontransplanted cases (post-HSCT MPN-MF: 2 cases;
nontransplanted MPN-MF: 1 case). Splenic vessels at hilum
were regular, with no evidence of thrombosis.
In comparison to normal controls, the spleens of trans-
planted and nontransplanted MF cases showed marked atro-
phy of the white pulp, with congested and effaced red pulp.
Gamna–Gandy bodies were abundant in all post-HSCT
cases, rare or absent in nontransplanted MPN-MF, and com-
pletely lacking in normal controls (Table 1 and Fig. 1).
Significant differences in the presence and composition
of EMH were observed between transplanted and nontrans-
planted MF spleens. In post-HSCT, residual EMH was either
absent (Case #1) or mild to moderate (EMH score 1+ in Case
#2; EMH score 2+ in Case #3). In Case 2, residual EMH was
almost exclusively composed by erythroid precursors, pref-
erentially located within the splenic sinusoids. In Case 3,
residual EMH was composed of erythroid and myeloid cells,
with rare atypical megakaryocytes within the splenic cords
and sinusoids. The EMH growth pattern was diffuse in the
first case and mixed (nodular and diffuse) in the other. By
contrast, in nontransplanted MPN-MF, splenic EMH was
widespread and severe (score 3+), featuring aggregates of
myeloid and erythroid precursors, with occasional clusters
of atypical megakaryocytes. The growth pattern was mixed
(nodular and diffuse) in all cases. EMH was located in both
the splenic sinusoids and red pulp cords (Table 1 and Fig. 1).
Fig. 2 Immunohistochemical features of the studied spleens. A-D. MPN-MF spleens. Both the transplanted and non-transplanted
spleens in MPN-associated MF were characterized by a high density of CD34-positive microvessels (A), a decreased frequency of CD8-
positive splenic sinusoids (B) and a high frequency of SMA-positive myoid cells (C) and NGFR-positive adventitial reticulum cells (D).
The immunohistochemical features of post-HSCT spleens were comparable with those of non-transplanted cases (not shown). E-H.
Normal controls. In normal spleens, the density of CD34-positive vessels (E) was significantly lower than in MF cases. Note the normal
frequency of CD8-positive sinusoids (F). The SMA-positive myoid cells (G) and NGFR-positive adventitial reticulum cells (H) were
normally distributed, found mostly around the splenic vascular structures. (Immunoperoxidase and reticulin stain; original
magnification 10x and 20x).
Post-transplant spleen histology in myelofibrosis 101In relation to splenic fibrosis, both transplanted and non-
transplanted MF disclosed reticulin and collagen deposition.
By contrast, normal controls did not show evidence of fibro-
sis. In MF cases, splenic fibrosis was not influenced by the
JAK2 mutational status and/or by the degree of EMH
(increased reticulin and collagen fibers were documented
even in the spleen without residual EMH after HSCT; Table 1
and Fig. 1).
No significant differences in spleen histology were noted
between JAK2V617F-positive and JAK2V617F-negative MF
patients in both the transplanted and nontransplanted sub-
groups. Also, the type and number of prior therapies did not
correlate with any considered histological parameter.
Immunohistochemical analysis of the red pulp vessels
and stromal cells disclosed differences between MF cases
and normal controls. Both transplanted and nontransplanted
MPN-MF spleens showed increased numbers of CD34-positive
microvessels compared with normal spleens (mean CD34-
positive microvessel density: 38.8/HPF in post-HSTC MF;
40.2/HPF in nontransplanted MF; 31.3/HPF in normal
spleens). The increase in CD34-positive microvessels was
associated with a reduction of CD8-positive sinusoids (mean
sinusoid density: 15.3/HPF in post-HSCT MF; 19.2/HPF in
nontransplanted MF; 45.6/HPF in normal spleens; Table 1
and Fig. 2). Compared with normal spleens, MPN-MF cases
had more SMA-positive myoid cells and more numerous
NGFR-positive adventitial reticulum cells. The quantity
and distribution of SMA-positive and NGFR-positive cells
roughly paralleled the extent and distribution of spleen
fibrosis (Fig. 2).
No differences in CD34-positive microvessels, CD8-
positive sinusoids, SMA-positive myoid cells, or NGFR-
positive adventitial reticulum cells were observed between
transplanted and nontransplanted MPN-MF. Of note, thenumber of SMA-positive or NGFR-positive cells did not corre-
late with the presence/extent of EMH.
Comparison between spleen and BM histology
Correlations between splenic and BM histology were also
investigated. Post-HSCT BM biopsies at the time of splenec-
tomy were available for two patients: one case with mild
splenic EMH, who achieved complete BM histologic response
<3 months after HSCT (Case #2); and one case with EMH
score 2+ and delayed CR (Case #3). In the first case, the
BM disclosed normal cellularity, with normal hematopoiesis,
no atypical megakaryocytes, and MF1 fibrosis, consistent
with CR [19]. In the second case, the BM biopsy showed
increased cellularity for patient age (90%), with atypical
megakaryocytes and MF1 fibrosis, consistent with clinical
improvement (revised International Working Group-
Myeloproliferative Neoplasms Research and Treatment and
European LeukemiaNet criteria) [19].
Discussion
PMF and post-PV MF are hematological neoplasms, charac-
terized by largely overlapping clinicopathologic features
and by a poor prognosis [22–24]. In spite of its significant
morbidity and mortality, HSCT remains the only curative
therapeutic modality with high CR rates and significant
improvement of the disease natural history [25,26].
Although the marrow histologic features of advanced stage
PMF, post-PV, and post-ET MF are well described [1,4,27–
30] and several studies have documented changes in pre-
HSCT versus post-HSCT BM [31–34], very little is known on
post-HSCT spleen histology in patients with MPN-MF. In
102 M. Pizzi et al.addition, no data are available on the relation between BM
changes (i.e., decreased cellularity, presence of atypical
megakaryocytes, degree of BM fibrosis) and any possible
change in spleen histology. To address these issues, we
compared the histologic features of spleens from trans-
planted and nontransplanted MPN-MF patients. Control
spleens were also evaluated for comparison. Spleen histol-
ogy in transplanted MF patients was compared with marrow
findings at the time of splenectomy.
Our results demonstrate that the weight of post-HSCT MF
spleens was markedly lower than that of nontransplanted
cases (2400 g vs. 3153 g) and that this difference is mostly
due to reduced EMH amounts in transplanted MF compared
with nontransplanted cases (Table 1). In addition, the histo-
logic composition of EMH significantly differed between
transplanted and nontransplanted cases, as large clusters
of atypical megakaryocytes were only faced in the nontrans-
planted group (Table 1 and Fig. 1). These differences consti-
tute the first histologically documented evidence that HSCT
reduces or abrogate neoplastic EMH in the spleen.
Gamna–Gandy bodies (sclero-siderotic nodules) were
largely restricted to the transplanted group. The reasons
of this finding are still unknown, but some explanatory
mechanisms may be proposed. Gamna–Gandy bodies are
the histologic hallmark of microvascular damage and scar-
ring. In our series, they may thus represent the vascular
cytotoxic effects of either conditioning or post-transplant
immune suppressive therapy (i.e., tacrolimus). The second
hypothesis may be more likely sustained by: (a) the well
reported vascular toxicity of calcineurin-inhibitors [35];
(b) the relative long time interval elapsed between HSCT
and splenectomy. Further studies are, however, needed to
clarify this issue.
Irrespective of the etiology of vascular damage, it is pos-
sible to speculate that these injuries may affect the capabil-
ity of the splenic vascular microenvironment in sustaining
pathologic hematopoiesis. EMH cells indeed reside intravas-
cularly in dilated splenic sinusoids or within abnormal
hematopoietic niches, which include endothelial cells,
fibroblasts, and histiocytes [36–39]. Endothelial cells and
fibroblasts of MPN-MF can sustain the differentiation of neo-
plastic megakaryocytes [40–43], regulate the mobilization
of neoplastic stem cells [38,44–46], and modulate the
expression of several chemokines and adhesion molecules
[40,41,47].
Compared with normal spleens, both transplanted and
nontransplanted MPN-MF spleens were also characterized
by a high density of CD34-positive microvessels, paralleled
by a decreased density of CD8-positive sinusoids. SMA-
positive and NGFR-positive stromal cells were both mark-
edly increased in all MPN-MF cases, irrespective of prior
treatments (Table 1 and Figs. 1 and 2). These changes are
in keeping with what was reported in a large series of MPNs,
including cases of PMF [16–18].
The absence of stromal changes after HSCT poses intrigu-
ing questions on the biological response to such therapy.
Two hypotheses can indeed explain the persistence of stro-
mal changes up to 176 days after HSCT: (a) less likely, an
inefficacy of HSCT to induce a complete stromal normaliza-
tion; and (b) more likely, the need of a long time for the
improvement of stromal changes. Recent literature data
seem to sustain the latter hypothesis. In particular, inMPN-MF, Ciurea and colleagues [33] reported a variable
reduction of spleen size after HSCT, with subsets of patients
requiring more than 36 months for complete resolution of
splenomegaly. In such cases, delayed spleen responses
may be attributable to a late resolution of red pulp fibrosis.
Such hypothesis is also sustained by recent studies on BM
histology in transplanted PMF patients, reporting a late
reduction of interstitial fibrosis in a consistent subgroup of
patients [31–34]. Similar time trends in fibrosis resolution
may indeed characterize two organs (the spleen and the
BM) involved by the same neoplastic process. This hypothe-
sis is sustained by the roughly comparable histologic
responses to HSCT found in our two patients with available
matched spleen and BM samples. One patient (Case #2)
showed complete disappearance of EMH in the spleen and
normal cellularity in the BM, while the second (Case #3)
showed residual neoplastic hematopoiesis in the spleen,
paralleled by increased cellularity and atypical megakary-
ocytes in the BM.
In conclusion, our study demonstrates that HSCT induces
marked histologic changes in the spleen of MPN-MF patients.
The HSCT-mediated splenic effects parallel similar changes
in the BM (normalization of cellularity and reduction of
megakaryocyte atypia), suggesting a possible common
mechanism in the response to therapy. In our series, HSCT
did not significantly affect splenic fibrosis (more time may
be needed to induce its regression). These results pose
intriguing questions on MPN-MF biology and on the splenic
effects of MF-related therapies. They are, however,
inferred from a relatively small number of cases and need
to be confirmed on larger and well-annotated cohorts of
patients. This will help clarify the still open issues concern-
ing the fascinating and complex topic of spleen involvement
in MPN-MF.
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